We scan new podcasts and send you the top 5 insights daily.
Alex Rives says continuous molecular monitoring would be immensely valuable and likely converge with cell models eventually. Measuring more molecular parameters continuously could directly link bottom-up personal health data with top-down biological understanding of disease, though Biohub itself stays at the enabling technology layer.
Alex Rives argues current virtual cell models fail because biology's measuring tools cannot observe the fine-grained causal structure models need. He says better architectures help, but Biohub is investing heavily in new measurement modalities and data generation because observation limits are the deeper bottleneck first.
To study complex processes like inflammation, CZI is developing technologies that go beyond analyzing existing data. This includes implantable sensors that track inflammatory markers in real-time (like a glucose monitor) and "live tissue omic platforms" that can map entire proteomes, creating rich, dynamic datasets to train advanced AI models.
CZI's New York Biohub is treating the immune system as a programmable platform. They are engineering cells to navigate the body, detect disease markers like heart plaques, record this information in their DNA, and then be read externally, creating a living diagnostic tool.
To build truly dynamic "virtual cells," two key technological hurdles must be overcome. First, developing high-throughput methods for measuring proteins, the cell's functional units. Second, inventing a sequencing technology that can measure the state of the *same cell* at multiple time points without destroying it.
Current medical AI relies on electronic health records, which capture only infrequent snapshots of a person's health. The next breakthrough will come from companies that create new, continuous data rails by engaging with patients longitudinally, generating proprietary "N-of-one" datasets for superior models.
Alex Rives says a complete cell model must include cells in tissue and living systems, not just isolated cultures. Biohub builds real imaging across atomic, cell-culture, and whole-organism scales, including zebrafish microscopes that track every cell and immune-cell trafficking as an embryo develops over time.
Genomic data (DNA) provides a static blueprint of potential, not a view of the actual biological activity. True understanding requires measuring the dynamic interactions of molecules and cells within tissues "downstream." Current methods capture only fragmentary slices, missing the full picture.
Alex Rives describes Biohub's Virtual Biology Initiative with DOE, NIH, Google DeepMind, Isomorphic, and Meta as a coordinated push to generate cellular data. Top priorities include spatial biology and cell atlases linking molecular and imaging measurements across hundreds of billions of healthy and diseased cells.
Alex Rives treats disease as a regular biological program encoded in human life, opening the door to programmable medicine. Reading and rewriting those programs could directly let interventions target underlying mechanisms rather than just surface symptoms, which is central to Biohub's ambitious human cure-all-disease mission.
Alex Rives says health-record models learn correlations, which can route existing drugs to the right patients better but won't uncover causal biology. Biohub instead focuses on fundamental measurement and models, arguing that without the right basis, patient-history AI cannot explain the truly deep underlying mechanisms of disease.